Medpace Holdings, Inc. $MEDP Shares Acquired by CW Advisors LLC

Key Points

• CW Advisors LLC increased its stake in Medpace Holdings, Inc. by 14.2%, owning 14,034 shares worth approximately $4.28 million as of their latest SEC filing.
• Insider trading activity has been notable, with President Jesse J. Geiger selling 41,801 shares, representing a 53.38% decrease in his holdings, while General Counsel Stephen P. Ewald also sold shares, indicating substantial insider selling.
• Several analysts have changed their ratings on Medpace, with Barclays setting a new target price of $450 and Cowen downgrading their rating from "buy" to "sell", reflecting varied market sentiments.

CW Advisors LLC boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 14.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 14,034 shares of the company's stock after acquiring an additional 1,746 shares during the quarter. CW Advisors LLC's holdings in Medpace were worth $4,276,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Mawer Investment Management Ltd. acquired a new stake in Medpace during the 1st quarter worth $212,131,000. Vulcan Value Partners LLC boosted its stake in Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after purchasing an additional 224,578 shares during the last quarter. Fundsmith LLP acquired a new stake in Medpace during the 4th quarter worth $42,372,000. Spyglass Capital Management LLC boosted its stake in Medpace by 85.1% during the 4th quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock worth $87,264,000 after purchasing an additional 120,778 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Medpace by 31.3% during the 4th quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock worth $159,532,000 after purchasing an additional 114,436 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the topic of several recent research reports. TD Cowen reissued a "sell" rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Barclays boosted their price objective on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price objective for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Truist Financial boosted their price objective on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $406.60.

Insider Buying and Selling

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the transaction, the vice president directly owned 57,500 shares in the company, valued at $25,883,050. This represents a 11.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 48,487 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the sale, the chief executive officer directly owned 962,615 shares of the company's stock, valued at $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 114,450 shares of company stock valued at $51,791,251 over the last three months. 20.30% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of MEDP stock traded down $0.38 during trading hours on Thursday, reaching $473.11. 130,808 shares of the stock were exchanged, compared to its average volume of 448,407. The business's fifty day moving average is $389.02 and its two-hundred day moving average is $337.53. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $501.30. The firm has a market capitalization of $13.29 billion, a P/E ratio of 35.13, a P/E/G ratio of 2.95 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm's revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.